> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Mirum Pharma Wins Priority Review Voucher
- URL: https://www.fdaweb.com/mirum-pharma-wins-priority-review-voucher/
- Published: 2024-08-28T12:00:00.000Z
- Updated: 2026-09-14T14:39:52.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5157665

*Federal Register* notice: FDA is announcing that it issued Mirum Pharmaceuticals a priority review voucher for its approved rare pediatric disease product Livmarli (maralixibat). FDA has determined that Livmarli, which is indicated for treating cholestatic pruritus in patients one year of age and older who have Alagille syndrome, meets the criteria for a priority review voucher. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2024-08-28/pdf/2024-19334.pdf?ref=fdaweb.com).